Updated statement on exiting the EU, and the British Pharmacopoeia
Following the result of the UK’s decision to exit the European Union (EU), there have been some questions about the future of the British Pharmacopoeia (BP) – particularly in the event of ‘No Deal’ between the UK and the EU.
We therefore would like to reiterate that the BP will continue to be part of the Medicines and Healthcare products Regulatory Agency’s public health role. The UK was a founding member of the Convention on the Elaboration of a European Pharmacopoeia and will continue to be a member of the European Pharmacopoeia (Ph. Eur) in any EU Exit scenario, as the UK will continue to be a member of the Council of Europe (CoE) in its own right.
More specifically, the standards of the Ph. Eur will continue to be adopted in the BP and the UK, and we will continue to reproduce the Ph. Eur in the BP for the convenience of our users.
Whatever the outcome, the BP will continue to add value to users in the UK, Europe and in the rest of the world through the provision of authoritative and high-quality standards.